• Início
  • Resultados da busca
  • A Two-Step Process of Effector Programming Governs CD4+ T Cell Fate Determination Induced by Antigenic Activation in the Steady State.

A Two-Step Process of Effector Programming Governs CD4+ T Cell Fate Determination Induced by Antigenic Activation in the Steady State.

Cell reports (2020-11-26)
Adeleye Opejin, Alexey Surnov, Ziva Misulovin, Michelle Pherson, Cindy Gross, Courtney A Iberg, Ian Fallahee, Jessica Bourque, Dale Dorsett, Daniel Hawiger
RESUMO

Various processes induce and maintain immune tolerance, but effector T cells still arise under minimal perturbations of homeostasis through unclear mechanisms. We report that, contrary to the model postulating primarily tolerogenic mechanisms initiated under homeostatic conditions, effector programming is an integral part of T cell fate determination induced by antigenic activation in the steady state. This effector programming depends on a two-step process starting with induction of effector precursors that express Hopx and are imprinted with multiple instructions for their subsequent terminal effector differentiation. Such molecular circuits advancing specific terminal effector differentiation upon re-stimulation include programmed expression of interferon-γ, whose production then promotes expression of T-bet in the precursors. We further show that effector programming coincides with regulatory conversion among T cells sharing the same antigen specificity. However, conventional type 2 dendritic cells (cDC2) and T cell functions of mammalian target of rapamycin complex 1 (mTORC1) increase effector precursor induction while decreasing the proportion of T cells that can become peripheral Foxp3+ regulatory T (pTreg) cells.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Phorbol 12-myristate 13-acetate, ≥99% (TLC), film or powder
Sigma-Aldrich
Ionomycin calcium salt from Streptomyces conglobatus, powder, ≥98% (HPLC)
Roche
Nutridoma-SP, suitable for hybridoma, solution, pkg of 100 mL (100x)
Sigma-Aldrich
Lys-Lys-Lys-Lys, ≥95% (TLC)
Sigma-Aldrich
Monoclonal Anti-IFNG antibody produced in mouse, clone G-23, purified immunoglobulin, buffered aqueous solution